- About MHRP
- International Network
- Prevention, Care & Treatment
- News & Publications
We're at the forefront of the battle against HIV to protect U.S. troops from infection and to reduce the global impact of the disease.
With U.S. troops deployed around the world, it is our mission to both protect U.S. military personnel and serve the international community by reducing risk of HIV-1 infection.
MHRP is at the forefront of the battle against HIV to protect U.S. troops from infection and to reduce the global impact of the disease. While its primary focus is developing a globally effective HIV-1 vaccine, the program provides prevention, care and treatment through the President’s Emergency Plan for AIDS Relief (PEPFAR).
MHRP is centered at the Walter Reed Army Institute of Research (WRAIR), U.S. Army Medical Research and Materiel Command.
MHRP was authorized by Congress in 1986, and since has become a leader in international efforts to combat HIV. With five sites in Africa and Asia, the program’s growth has been achieved through the combination of strong vaccine science, the careful development of research sites, and partnerships with key research institutions in the U.S. and host countries.
The integration of prevention, care and treatment has helped MHRP build strong and trusting relationships with the communities in which research is conducted, while providing an ethical framework to conduct HIV clinical research.
The program’s network includes international laboratory and clinical research capabilities. MHRP has developed research sites in Tanzania, Kenya, Nigeria, Uganda and Thailand. MHRP’s main laboratories are located in Rockville, Maryland.
The investigational HIV vaccine regimen that showed a modestly protective effect in the landmark RV144 clinical trial conducted in Thailand was shown to be safe and elicited robust immune responses when tested among 100 healthy adults in South Africa, according to findings presented today at the HIVR4P conference in Cape Town, South Africa.
MHRP and collaborators will present at the 2014 HIV Research for Prevention Conference (R4P) in Cape Town, South Africa, October 26 - 31st.
COL Jerome Kim will transition in 2015 to become the Director-General of the International Vaccine Institute (IVI), a Seoul-based non-profit devoted to research in vaccine development and delivery.
Dr. Jintanat Ananworanich gave a plenary presentation this week at AIDS 2014.